PharmaTher Plans 3D-Printed Oral KPV and BPC-157 Products
PharmaTher says it will develop personalized oral products for GI use via the U.S. 503A peptide pathway, using Craft Health’s CORR3CT technology for colon targeting. Commercialization is subject to policy conditions; neither peptide is FDA-approved.